Business Segments Precigen, Inc.

Equities

Market Closed - Nasdaq Other stock markets 04:00:00 2026-04-10 pm EDT			5-day change	1st Jan Change
4.160 ^USD	-2.58%		+5.58%	-0.48%

Apr. 07	Precigen Expects Q1 Revenue to Surpass $18 Million Due to Strong Uptake of Recurrent Respiratory Papillomatosis Drug	MT
Apr. 07	(PGEN) Precigen Expects Q1 Revenue to Exceed $18M, vs. FactSet Est of $20.8M	MT

Breakdown by Business Segment (USD)

Fiscal Period: December	2021	2022	2023	2024	2025
Gene Research and Development
Biotechnology (Startups)	-	-	-	-	9.68M
Total Assets	-	-	-	-	156M
Interest Expense	-	-	-	-	-3.87M
Income Tax Expense	-	-	-	-	3K
CAPEX	-	-	-	-	-2M
EBT	-	-	-	-	-251M
D&A	-	-	-	-	3.2M
Operating Income	-	-	-	-	-111M
Net Income	-	-	-	-	-251M
Exemplar	13.34M	12.02M	6.15M	3.92M	-
CAPEX	-	-	-	-47K	-
EBITDA	6.9M	5M	-726K	-929K	-
Biopharmaceuticals	2.56M	16.34M	75K	-	-
CAPEX	-	-	-	-8.48M	-
EBITDA	-45.75M	-45.04M	-75.34M	-82.29M	-
Pgen Therapeutics	-	-	-	-	-
EBITDA	-	-	-	-	-
Synthetic Biology Technologies	-	-	-	-	-
Interest Expense	-	-	-	-	-
Income Tax Expense	-	-	-	-	-
Total Assets	-	-	-	-	-
CAPEX	-	-	-	-	-
EBT	-	-	-	-	-
D&A	-	-	-	-	-
Operating Income	-	-	-	-	-
Net Income	-	-	-	-	-
Pharmaceutical Products
Human Biotherapeutics	-	-	-	-	-
EBITDA	-	-	-	-	-
Eliminations	-2.07M	-1.45M	-	-	-
EBITDA	-2.06M	-1.55M	-	-	-
EBITDA	-33.51M	-32.91M	-	-	-
Pharmaceutical Contract Research Organization
ALL Other	-	-	-	-	-
EBITDA	-	-	-	-	-
Agricultural Biotechnology
Actobio	-	-	-	-	-
EBITDA	-	-	-	-	-
Trans Ova	90.04M	-	-	-	-
EBITDA	17.42M	-	-	-	-
Methane Bioconversion Platform Titan	-	-	-	-	-
EBITDA	-	-	-	-	-

Geographical breakdown of sales (USD)

Fiscal Period: December	2021	2022	2023	2024	2025
United States of America	103M	26.68M	6.22M	3.92M	9.68M
Total Assets	-	-	-	-	156M
Interest Expense	-	-	-	-	-3.87M
Income Tax Expense	-	-	-	-	3K
D&A	-	-	-	-	3.2M
CAPEX	-	-	-	-	-2M
Net Income	-	-	-	-	-251M
EBT	-	-	-	-	-251M
Operating Income	-	-	-	-	-111M
Foreign Countries	530K	233K	-	-	-